NCT05657574 - A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia | Biotech Hunter

Enrollment

228

Participants

Timeline

Start Date

November 24, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions

Primary Hypercholesterolemia

Interventions

DRUG

D377

oral, once daily, 8 weeks

DRUG

CKD-331

oral, once daily, 8 weeks

DRUG

D086

oral, once daily, 8 weeks

DRUG

Placebo (for D377)

oral, once daily, 8 weeks

DRUG

Placebo (for CKD-331)

oral, once daily, 8 weeks

DRUG

Placebo (for D086)

oral, once daily, 8 weeks

Trial Locations (1)

RECRUITING

Asan Medical Center, Seoul